Omar Hanuch, MD
Ophthalmology · Rochester, NYNPI 1316929334
Payments from drug & device makers
Across 145 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Sight Sciences, Inc.$485
- Johnson & Johnson Surgical Vision, Inc.$450
- Sun Pharmaceutical Industries Inc.$365
- Bausch & Lomb Americas Inc.$271
- AbbVie$191
- plus $923 from 15 others
What the payments were for
- Food & beverage$4,199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 45 | $1,514 |
| Sight Sciences, Inc. | 13 | $485 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $450 |
| Sun Pharmaceutical Industries Inc. | 12 | $365 |
| Bausch & Lomb Americas Inc. | 9 | $271 |
| AbbVie(2 entities) | 8 | $191 |
| Novartis | 9 | $147 |
| Tarsus Pharmaceuticals, Inc. | 5 | $131 |
| Aerie Pharmaceuticals, Inc. | 7 | $103 |
| Oyster Point Pharma, Inc. | 4 | $85 |
| Rxsight Inc | 1 | $78 |
| Astellas Pharma US Inc | 2 | $66 |
| Kala Pharmaceuticals, Inc. | 3 | $60 |
| Biotissue Holdings Inc. | 4 | $59 |
| Thea Pharma Inc. | 2 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| Ivantis, Inc | 2 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Alcon Research LLC | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$592
- MIEBO$125
- XIIDRA$125
- CEQUA$125
- OMNI(R) SURGICAL SYSTEM (US)$120
- Tecnis Simplicity$117
- Clareon PanOptix Pro$116
- OMNI$112
- AcrySof IQ PanOptix$110
- Catalys Laser System$103
How this compares
$4,199 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $52,744 |
| XiidraLifitegrast | 34 | $48,137 |
| LumiganBimatoprost | 56 | $27,634 |
| RocklatanNetarsudil Mesylat/Latanoprost | 68 | $27,448 |
| Cyclosporine | 39 | $22,336 |
| Prednisolone Acetate | 228 | $9,578 |
| Latanoprost | 539 | $7,255 |
| Brimonidine Tartrate | 132 | $6,765 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 353 | $5,702 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $5,497 |
| Timolol Maleate | 262 | $5,050 |
| Ketorolac Tromethamine | 119 | $4,952 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 175 | $2,263 |
| Difluprednate | 17 | $2,170 |
| Dorzolamide Hcl | 25 | $705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $191 | $80,37895 claims |
| Bausch & Lomb Americas Inc.Xiidra | $271 | $48,13734 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $103 | $27,44868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Rochester
- Paul HartmanRochester$1.6M
- David KleinmanRochester$730K
- Alan GruberRochester$429K
- James AquavellaRochester$192K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.